Arek Z. Dudek, MD, PhD
Dr. Arkadiusz Z. Dudek is a medical oncologist and researcher at the Mayo Clinic in Rochester, Minnesota. He is actively involved in developing new cancer therapeutics for lung cancer, malignant mesothelioma, kidney cancer, and melanoma, as well as other advanced malignancies. His focus is on identifying targets for therapies in order to lead to improvements in length of disease control and survival.[1]
Education and Career
Dr. Dudek earned his medical degree at the Medical University of Warsaw in Poland and then pursued a clinical internship in Internal Medicine at Polyclinic Medical Center. He then completed a clinical fellowship in Bone Marrow Transplantation at Johns Hopkins University Hospital, a clinical residency in Internal Medicine at Polyclinic Medical Center and a visiting residency in Gastroenterology and Rheumatology at the Milton S. Hershey Medical Center, a fellowship in Hematology, Oncology, and Transplantation at the University of Minnesota, and a Ph.D. in Medical Sciences/Oncology at the Military Medical Institute.[1]
After completing his medical education and training, he accepted a role as a member and co-chair of the Thoracic Oncology Program at the University of Minnesota Comprehensive Cancer Center, also heading up clinical research for the division of Hematology, Oncology and Transplantation and the Solid Tumor Oncology Cancer Experimental Therapeutics Initiative there. He later became the director of the clinical trials office and leader of the Cancer Target and Therapeutics Program at the University of Illinois Cancer Center before joining the Health Partners Cancer Research Center part-time and the Mayo Clinic.[1]
Professional Memberships and Activities
Dr. Dudek is an active member of several professional associations and organizations and has been involved in numerous clinical research committees including:[1]
NCI, GI Steering Committee
Steering Committee Member, Big Ten Cancer Research Consortium
International Association for the Study of Lung Cancer
American College of Physicians
University of Minnesota Cancer Center
American Association for Cancer Research
American Society of Clinical Oncology
American Society of Hematology
European Society of Medical Oncology
Research
Dr. Dudek is a prolific researcher and author who has published more than 100 articles and studies that have appeared in peer-reviewed medical journals. His research interests include the treatment of lung cancer, melanoma, and kidney cancer. He has also written several editorials and book chapters on topics including tumor biology and targeted cancer therapies.
His recent research activities and funding include:[1]
Phase Ib and Phase II Studies of anti-PD-1 Antibody MK-3475 in Combination with Bevacizumab for the Treatment of Metastatic Renal Cell Carcinoma: Big Ten Cancer Research Consortium BTCRC-GU14-003.
Source: Investigator Initiated Trial, supported by Merck.
Role: Principal Investigator 06/30/2017-06/29/2020
Phase II Study of Nivolumab and Ramucirumab for Patients with Previously Treated Mesothelioma: HCRN LUN15-299
Source: Investigator Initiated Trial, supported by Eli Lilly and Bristol-Myers Squibb.
Role: Study Chair 10/30/2018-06/29/2021
Dr. Dudek’s recent publications include:[1]
· Phase 2 trial of nivolumab and ramucirumab for relapsed mesothelioma: HCRN-LUN15-299.
JTO Clin Res Rep. 2023
Neurooncol Adv. 2023
· Phase I study of procaspase-activating compound-1 (PAC-1) in the treatment of advanced malignancies.
British Journal of Cancer. 2023
· The combination of PAC-1 and entrectinib for the treatment of metastatic uveal melanoma.
Melanoma Research. 2023
Clinical Cancer Research. 2022
